As of November 13, 2026, U.S. officials were considering new restrictions on concentrated 7-OH products, while saying they were not targeting traditional botanical kratom. The distinction matters to people who report benefits from these products—and to those who say they became dependent on them.
7-OH, short for 7-hydroxymitragynine, occurs naturally in very small amounts in kratom, a plant in the coffee family. Concentrated 7-OH products are sold as tablets, gummies and other forms, sometimes alongside other semi-synthetic opioids. Researchers and officials say some users show signs of addiction, while unclear labeling can make it difficult to know how much of a substance a product contains.
In August 2026, the Drug Enforcement Administration restricted the manufacture and sale of three semi-synthetic opioids derived from 7-OH and related compounds: MGM-15, MGM-16 and mitragynine pseudoindoxyl, or MGPI. After the American Kratom Association sued over concerns about trace amounts of MGPI in natural kratom, the Department of Health and Human Services issued a new recommendation on October 9. The DEA then planned a narrower restriction focused on products with higher concentrations of 7-OH and/or MGPI. At the time of the November 13 report, that further restriction had not yet taken effect and could begin as early as that day.
Evidence about harms and benefits remains limited. A report using data from 53 U.S. poison control centers found that kratom-related call reports rose about 1,200% between 2015 and 2025. It recorded 233 deaths associated with kratom during that period; 79% involved multiple substances. The data did not distinguish traditional kratom from products such as concentrated 7-OH, so those figures cannot establish the risk of either product on its own.
People interviewed described sharply different experiences. Angela Wilson, 44, said 7-OH helped her manage chronic pain related to endometriosis and symptoms of depression; she worried that losing access would be devastating for her family. Tyler, 38, said he first used kratom powder while stopping opioids, but later became dependent on 7-OH tablets and entered a detox program after repeated attempts to stop. A National Institute on Drug Abuse researcher said his ongoing research suggests dependence risk may be higher with 7-OH products than with whole-leaf kratom. That finding is not a settled measure of risk, and individual accounts cannot establish whether a product is safe or effective as treatment.